Tuesday was a relatively uneventful news day for Pfizer, especially following the pharmaceutical giant's disclosure on Monday ...

Pfizer's strong R&D pipeline, 7.5%+ dividend yield, & undervalued PE ratio make PFE stock a compelling investment opportunity ...

One analyst tracking the pharmaceutical stock didn't hesitate to ... Bernstein SocGen's Courtney Breen wrote in her analysis, according to reports, that Pfizer will likely turn to its tried ...

Discover how Viking Therapeutics, Inc.'s VK2735 and VK2809 target obesity and NASH markets. Click for my updated look at VKTX ...

Pfizer (PFE) is ending a late-stage trial of its once-daily GLP-1 pill, Danuglipron, after a participant experienced a liver ...

BEIJING (Reuters) -China's top disease control official has said the country is formally considering mixing COVID-19 vaccines as ...

A study identifies three clinically distinct profiles of patients with vitiligo on the basis of emotional, psychological, and ...

Positive early stage data for Verve Therapeutics Inc.’s base editing therapy points to a range of development options, including bringing partner Eli Lilly and Co. in a little closer. Verve’s Heart-2 ...

Relay Therapeutics, Inc.’s RLAY share price has dipped by 6.34%, which has investors questioning if this is right time to buy ...

Beam Therapeutics Inc.’s BEAM share price has surged by 5.12%, which has investors questioning if this is right time to sell.

When Trump announced the 25% auto tariffs on March 27, he described them as “permanent.” His hard lines on trade have become ...